Alter ≥ 75 + ECOG ≥ 2 + signifikante Komorbidität — gleichzeitige CRT und Platin-doublet Chemo p...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | RF-NSCLC-FRAILTY-AGE |
|---|---|
| Art | Warnhinweis |
| Status | pending_clinical_signoff |
| Erkrankungen | DIS-NSCLC |
| Quellen | SRC-ESMO-NSCLC-EARLY-2024 SRC-NCCN-NSCLC-2025 |
Ursprung der Roten Flagge
| Begriffsbestimmung | Age ≥75 + ECOG ≥2 + significant comorbidity — concurrent CRT and platinum-doublet chemo poorly tolerated; consider sequential CRT, weekly chemo + ICI, or single-agent / best-supportive-care for fragile patients. |
|---|---|
| Klinische Richtung | Eskalation |
| Kategorie | Gebrechlichkeit |
Logik auslösen
{
"all_of": [
{
"comparator": ">=",
"finding": "age_years",
"threshold": 75
},
{
"any_of": [
{
"comparator": ">=",
"finding": "ecog_status",
"threshold": 2
},
{
"comparator": ">=",
"finding": "comorbidity_count",
"threshold": 2
}
]
}
],
"type": "composite_clinical"
}
Anmerkungen
Geriatric assessment (G8 / CGA) recommended pre-treatment for ≥70. PD-L1≥50% driver-negative elderly: pembrolizumab mono is the best-tolerated option preserving OS benefit.
Verwendet von
Algorithmen
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L
Kapitel des Handbuchs
HB-NSCLC-METASTATIC-1L- Metastatische NSCLC: Treiber-Erstbehandlungs-Hintergrund
Anwendungsgebiet
IND-NSCLC-2L-BRAF-V600E-DAB-TRAM- IND-NSCLC-2L-BRAF-V600E-DAB-TRAMIND-NSCLC-2L-DOCETAXEL-RAMUCIRUMAB- IND-NSCLC-2L-DOCETAXEL-RAMUCIRUMABIND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMAB- IND-NSCLC-2L-EGFR-EX20INS-AMIVANTAMABIND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZ- IND-NSCLC-2L-EGFR-POST-OSI-AMI-LAZIND-NSCLC-2L-HER2-MUT-T-DXD- IND-NSCLC-2L-HER2-MUT-T-DXDIND-NSCLC-2L-KRAS-G12C-ADAGRASIB- IND-NSCLC-2L-KRAS-G12C-ADAGRASIBIND-NSCLC-2L-KRAS-G12C-SOTORASIB- IND-NSCLC-2L-KRAS-G12C-SOTORASIBIND-NSCLC-2L-MET-AMP-CAPMATINIB- IND-NSCLC-2L-MET-AMP-CAPMATINIBIND-NSCLC-2L-MET-EX14-CAPMATINIB- IND-NSCLC-2L-MET-EX14-CAPMATINIBIND-NSCLC-2L-MET-EX14-TEPOTINIB- IND-NSCLC-2L-MET-EX14-TEPOTINIBIND-NSCLC-2L-NTRK-LAROTRECTINIB- IND-NSCLC-2L-NTRK-LAROTRECTINIBIND-NSCLC-2L-PD-L1-POST-IO-DOCETAXEL- IND-NSCLC-2L-PD-L1-POST-IO-DOCETAXELIND-NSCLC-2L-RET-FUSION-SELPERCATINIB- IND-NSCLC-2L-RET-FUSION-SELPERCATINIBIND-NSCLC-EGFR-1L-AMI-LAZ- IND-NSCLC-EGFR-1L-AMI-LAZIND-NSCLC-EGFR-1L-OSI-CHEMO- IND-NSCLC-EGFR-1L-OSI-CHEMO